Approved CAR-T therapies have reproducible efficacy and safety in clinical practice
Daniel Goyco Vera, Hiral Waghela, Mohamed Nuh, Jonathan Z. Pan, Premal Lulla
Abstract
CAR-T cell therapy has established itself as a highly effective treatment for hematological malignancies. There are currently six commercial CAR-T products that have been FDA approved for diseases such as B-ALL, LBCL, MCL, FL, MM, and CLL/SLL. "Real-world" studies allow us to evaluate outcomes from the general population to determine their efficacy and safety compared to those who were included in the original trials. Based on several well conducted "Real-world" studies that represent diverse populations, we report that outcomes from the original trials that led to the approval of these therapies are comparable to those in practice.
Topics & Concepts
MedicineClinical trialClinical PracticeSafety profileCAR T-cell therapyPopulationIntensive care medicineOncologyInternal medicineAdverse effectFamily medicineChimeric antigen receptorCancerEnvironmental healthImmunotherapyCAR-T cell therapy research